, Volume 105, Issue 3, pp 319-326,
Open Access This content is freely available online to anyone, anywhere at any time.
Date: 01 Feb 2007

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro

Wittich Family Fund for Emerging Therapies in Breast Cancer. DOD Innovator Award W81XWH-05-1-0395
NCI Program Project Grant P01 CA032737:21. RSF is a recipient of an NIH-LRP Award